Business Context and Reporting Period
This Form 8-K filing by Gossamer Bio, Inc. (GOSS) reports on events occurring on May 18, 2020, with the report dated May 21, 2020. The filing details the entry into material definitive agreements for two simultaneous capital raising transactions: a public offering of common stock and a public offering of convertible senior notes.
Key Financial Metrics and Capital Structure
Common Stock Offering
- Shares Issued: 9,433,963 shares of common stock.
- Public Offering Price: $13.25 per share.
- Underwriting Price: $12.455 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 1,415,094 additional shares.
Convertible Senior Notes Offering
- Principal Amount: $200.0 million aggregate principal amount of 5.00% convertible senior notes due 2027.
- Interest Rate: 5.00% per annum, payable semi-annually starting December 1, 2020.
- Maturity Date: June 1, 2027.
- Underwriting Price: 97% of principal amount.
- Over-Allotment Option: Underwriters granted a 13-day option to purchase up to an additional $30.0 million in notes.
- Conversion Terms: Initial conversion rate of 61.6095 shares per $1,000 principal amount (approx. $16.23 per share).
Use of Proceeds
Net proceeds from both offerings are designated to fund research and development of product candidates, development programs, and for working capital and general corporate purposes.
Material Changes and Debt Obligations
The filing represents a significant change in the company's capital structure through the issuance of new equity and debt. The Notes are senior unsecured obligations, ranking senior to any subordinated indebtedness but effectively subordinated to existing and future secured indebtedness, including the company's credit agreement with MidCap Financial Trust. The filing does not provide comparative financial metrics (revenue, profit, cash flow) as this is a transactional report rather than a periodic financial statement.
Outlook, Risks, and Contingencies
Redemption and Repurchase Provisions
- Company Redemption: The Company cannot redeem the Notes prior to June 6, 2024. After this date, redemption is permitted if the stock price exceeds 130% of the conversion price for a specified period.
- Fundamental Change Repurchase: Holders may require the Company to repurchase notes at 100% of principal plus accrued interest if a fundamental change occurs prior to maturity.
Conversion Triggers
Holders may convert notes under specific conditions, including if the stock price exceeds 130% of the conversion price for 20 trading days in a quarter (after September 30, 2020), or during specific trading price dips relative to the conversion value. Conversion is also permitted at any time from March 1, 2027, until maturity.
Risks
The Notes contain customary events of default. In the event of bankruptcy, insolvency, or reorganization, the principal and accrued interest become immediately due and payable. The filing notes that the description of agreements is qualified by reference to the full text of the exhibits.
Investor Verification Checklist
- Verify the final closing amounts of the Common Stock and Convertible Notes offerings, including whether over-allotment options were exercised.
- Review the full text of the Indenture (Exhibit 4.1 and 4.2) for detailed covenants and conversion adjustment mechanisms.
- Confirm the impact of the new debt on the company's existing credit agreement with MidCap Financial Trust.
- Monitor the stock price relative to the $16.23 initial conversion price to assess potential dilution from note conversions.
- Check subsequent filings for the actual net proceeds received after underwriting discounts and offering expenses.